

# Special Issue

## Oral Cancer and COVID-19

### Message from the Guest Editor

Cancer is one of the leading diseases causing death in industrialized countries, despite numerous prevention campaigns and recent advances in medical treatments. The etiopathogenesis of cancer is varied, but it seems that some viruses may also be implicated. COVID-19 is a disease caused by the SARS-CoV-2 virus. Some authors have highlighted that the SARS-CoV-2 virus penetrates the host cell using cellular receptors of the angiotensin converting enzyme 2 (ACE2), which are well expressed in the oral mucosa and the EMMPRIN receptor, the inducer of extracellular matrix metalloproteinase. It appears that the two potential receptors of SARS-CoV-2, ACE2 and EMMPRIN have effects on the progression of oral tumors.

### Guest Editor

Dr. Francesco D'Ambrosio

Department of Medicina and Surgery, Schola Medica Salernitana, Via Salvador Allende, Baronissi, Italy

### Deadline for manuscript submissions

closed (1 July 2024)



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/188952](https://mdpi.com/si/188952)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)